Explore strategies for adjusting chemotherapy dosages based on genetic mutations, enhancing patient safety and treatment efficacy in clinical practice.
Jonathan Lee, MD, MSc
Advertisement
Jonathan Lee, MD, MSc, is a chief Hematology/Oncology Fellow at Weill Cornell Medicine.
Articles by Jonathan Lee, MD, MSc
Experts discuss the importance of real-world data in pancreatic cancer treatment, highlighting its impact on patient management and survival outcomes.
Experts discuss the importance of real-world data in pancreatic cancer treatment, highlighting its impact on patient management and survival outcomes.
Experts discuss the importance of real-world data in pancreatic cancer treatment, highlighting its impact on patient management and survival outcomes.
Jonathan Lee, MD, MSc, offers his tips for interviewing for a hematology/oncology fellowship.
Experts discuss evolving treatment strategies for metastatic pancreatic cancer, comparing NALIRIFOX and FOLFIRINOX in first-line therapy decisions.
Experts discuss evolving treatment strategies for metastatic pancreatic cancer, comparing NALIRIFOX and FOLFIRINOX in first-line therapy decisions.
Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc discuss advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS.
The chief oncology/hematology fellow at Weill Cornell Medicine details everything that he wishes he had known entering his first year of fellowship.
Advertisement
Latest Updated Articles
Understanding Your New Role as a Hematology/Oncology FellowPublished: September 3rd 2025 | Updated:
Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MScPublished: November 14th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5